Literature DB >> 11874080

Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma.

P L Cherchi1, V Marras, G Capobianco, G Ambrosini, M D Piga, G M Fadda, N Rosas, S Dessole.   

Abstract

OBJECTIVE: To assess the immunohistochemical expression of p53 protein, a tumour suppressor gene of the oncogene c-erb-B2 and MIB-1 proliferation marker (Ki-67 antigen) in endometrial carcinoma.
METHODS: We studied 29 cases of endometrial carcinoma in which the p53, c-erb-B2 and MIB-1/Ki-67 antigens were investigated by an immunohistochemical method. We evaluated the correlations among the immunohistochemical positivity and the grading, depth of myometrial invasion, stage of the neoplasia and follow-up.
RESULTS: Both p53 and c-erb-B2 were positive in 16 out of 29 cases (55.2%), whereas MIB-1 was positive in 19 out of 29 cases (65.5%). All these three antigens showed a positive correlation with the grading, myometrial invasion and FIGO stage. Regarding follow-up, p53, c-erb-B2 and MIB-1 were, respectively, positive in 100%, 83.4% and 66.7% of neoplasias of patients who died of disease whereas they were positive in 40%, 40% and 60%, respectively, of tumours of patients with no evidence of disease.
CONCLUSION: The overexpression of p53, c-erb-B2 and MIB-1 seem to indicate a more malignant tumour phenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11874080

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  4 in total

Review 1.  Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.

Authors:  Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

2.  Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.

Authors:  Basil R Obeidat; Ismail I Matalka; Alia A Mohtaseb; Nabih S Al-Kaisi
Journal:  Pathol Oncol Res       Date:  2012-10-10       Impact factor: 3.201

3.  Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.

Authors:  John Farley; Sartoru Fuchiuji; Kathleen M Darcy; Chunqiao Tian; William J Hoskins; William P McGuire; Parviz Hanjani; David Warshal; Benjamin E Greer; Jerome Belinson; Michael J Birrer
Journal:  Gynecol Oncol       Date:  2009-03-09       Impact factor: 5.482

4.  Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients.

Authors:  Maria Lambropoulou; Nikolaos Papadopoulos; Grigoris Tripsianis; George Alexiadis; Olga Pagonopoulou; Anastasia Kiziridou; Vassilios Liberis; Stylianos Kakolyris; Ekaterini Chatzaki
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.